The massive success of cell and gene therapies in recent years has made the need for effective, large scale vector engineering greater than ever. Though R&D efforts focussed on reducing immunogenicity and toxicity whilst improving redosing ability and durability are showing promise, companies are still striving to optimise these technologies and develop next-generation targeted, persistent and tolerable cell and gene therapies.
The Vector Development for Cell and Gene Therapy Summit is North America’s only event focused exclusively on addressing challenges in vector improvement for both ex vivo and in vivo approaches. Bringing together key industry leaders and covering a range of topics including capsid optimisation using AAV vectors, process optimisation using lentiviral and adenoviral vectors, innovative non-viral delivery options and the importance of vector serotype for improved durability, it’s a key opportunity to gain the actionable insights you’ll need to optimise your manufacturing process and improve tissue-specific targeting and safety profiles for your pipeline.
Event Venue: Hilton Boston Back Bay, 40 Dalton St, Boston, MA 02115, United States
Event Website: https://hubs.ly/Q01c-M4h0
Event Organizer: Kisaco Research
Contact No: +44 (0)20 3696 2920
Email ID: events@kisacoresearch.com
